Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus

Journal of Diabetes

Volumn 5, Issue 2, 2013, Pages 127-135

  Cui, Yi Min ^a   Guo, Xiao Hui ^a   Zhang, Dong Mei ^a   Tham, Lai San ^b   Tang, Cheng Cai ^b   Mace, Kenneth ^c   Linnebjerg, Helle ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Lilly NUS Centre for Clinical Pharmacology   (Singapore)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Chinese; Diabetes; Exenatide; Glucagon like peptide 1; Pharmacokinetics

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHINESE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET; DISEASE DURATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG TOLERANCE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 84877020930     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12020     Document Type: Article

References (24)

1. Yang W, Lu J, Weng J etal. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-1101.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
3. Stratton IM, Adler AI, Neil HA etal. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000; 321: 405-412.
4. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117: 77-88.
5. Edwards CM, Stanley SA, Davis R etal. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281: E155-161.
6. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002; 87: 1282-1290.
7. Kolterman OG, Buse JB, Fineman MS etal. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 3082-3089.
8. European Medicines Agency. Bydureon: European public assessment report: Summary for the public. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002020/human_med_001457.jsp&mid=WC0b01ac058001d124 (accessed 22 Janaury 2013).
9. US Food and Drug Administration. Bydureon: Drug details: Label information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (accessed 22 January 2013).
10. Zhao X, Cui YM, Zhou Y etal. Exenatide pharmacokinetics in healthy Chinese subjects. Int J Clin Pharmacol Ther. 2008; 46: 459-465.
11. Kim D, MacConell L, Zhuang D etal. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30: 1487-1493.
12. Drucker DJ, Buse JB, Taylor K etal. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet. 2008; 372: 1240-1250.
13. Diamant M, Van Gaal L, Stranks S etal. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet. 2010; 375: 2234-2243.
14. Cuddihy RM, Russell-Jones D, Hanefeld M etal. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes. Diabetes. 2011; 60 (Suppl. 1): A77 (Abstract).
15. Blevins T, Pullman J, Malloy J etal. DURATION 5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96: 1301-1310.
16. Bergenstal RM, Wysham C, MacConell L etal. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomized trial. Lancet. 2010; 376: 431-439.
17. Buse JB, Nauck M, Forst T etal. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet. 2012; 381: 117-124.
18. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of A WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Geneva, 1999.
19. Fineman MS, Mace KF, Diamant M etal. Clinical relevance of anti-exenatide antibodies: Safety, efficacy, and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012; 14: 546-554.
20. Iwamoto K, Nasu R, Yamamura A etal. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. 2009; 56: 951-962.
21. Fineman M, Flanagan S, Taylor K etal. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011; 50: 65-74.
22. US Food and Drug Administration. Byetta® (Exenatide) injection full prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BYETTA&CFID=7882409&CFTOKEN=bfd96f44989db3cc-55032381-F625-B480-0D39DC2F4283AF5B (accessed 20 February 2012).
23. International Conference on Harmonisation. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline. Ethnic Factors in the Acceptability of Foreign Clinical Data e5(r1). 1998 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf (accessed 16 September 2011).
24. Kothare PA, Linnebjerg H, Isaka Y etal. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008; 48: 1389-1399.